Decoy receptor 1
Decoy receptor 1 (DcR1), also known as TRAIL receptor 3 (TRAILR3), is a protein that in humans is encoded by the TNFRSF10C gene. It is a member of the tumor necrosis factor receptor superfamily, and is a key player in the regulation of apoptosis and immune response.
Structure[edit]
DcR1 is a type I transmembrane protein with an extracellular domain consisting of three cysteine-rich repeats, similar to other members of the tumor necrosis factor receptor superfamily. However, unlike most other family members, it lacks an intracellular death domain. This means it cannot induce apoptosis, but instead serves as a decoy receptor that can bind to its ligand, TRAIL, without triggering a cell death signal.
Function[edit]
The primary function of DcR1 is to protect cells from apoptosis by serving as a decoy receptor for TRAIL. By binding to TRAIL, it prevents the ligand from interacting with the death receptors DR4 and DR5, thereby inhibiting the induction of apoptosis. This function is crucial in immune regulation, as it prevents excessive cell death and maintains immune homeostasis.
Clinical significance[edit]
Alterations in the expression of DcR1 have been implicated in a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. In cancer, for example, overexpression of DcR1 can protect tumor cells from apoptosis, contributing to tumor progression and resistance to therapy. Conversely, downregulation of DcR1 has been observed in autoimmune diseases, potentially leading to excessive cell death and tissue damage.
See also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian